Search research articles
Contact Us
Filters
Showing results (71-80 of 99) with videos related to
Page
of 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus
Vincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV
Edgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Pamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Frontiers in Medicine
|
January 29, 2026
Differential socioeconomic, psychosocial, and behavioral factors associated with psychological distress and uncontrolled blood pressure among women with and without HIV in the US
Jenni M Wise, Emily B Levitan, Elizabeth A Jackson, et al.
AIDS (London, England)
|
December 16, 2022
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV
Pamela S Douglas, Sara McCallum, Michael T Lu, et al.
AIDS (London, England)
|
September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
Brian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Open Forum Infectious Diseases
|
March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy
Cynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 19, 2024
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function
Kristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
The Lancet. HIV
|
October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Hans Jaeger, Edgar T Overton, Gary Richmond, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 99) with videos related to
Sort By:
Page
of 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 11, 2021
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus
Vincent C Marconi, Carlee Moser, Christina Gavegnano, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV
Edgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Pamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Frontiers in Medicine
|
January 29, 2026
Differential socioeconomic, psychosocial, and behavioral factors associated with psychological distress and uncontrolled blood pressure among women with and without HIV in the US
Jenni M Wise, Emily B Levitan, Elizabeth A Jackson, et al.
AIDS (London, England)
|
December 16, 2022
Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV
Pamela S Douglas, Sara McCallum, Michael T Lu, et al.
AIDS (London, England)
|
September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
Brian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Open Forum Infectious Diseases
|
March 7, 2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy
Cynthia L Gay, Ronald J Bosch, Ashley McKhann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 19, 2024
Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function
Kristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
The Lancet. HIV
|
October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Hans Jaeger, Edgar T Overton, Gary Richmond, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Page
of 10